Teva Pharmaceuticals and Medincell recently received approval from the FDA for UZEDY™, an extended-release subcutaneous injectable form or risperidone for the treatment of schizophrenia in adults. Uzedy™ is based, in part, on technology developed by researchers at Penn, including Steven Siegel, MD, PhD, a former Penn Professor with a primary appointment in Psychiatry at Penn Medicine and a secondary appointment in Bioengineering at Penn Engineering, and Karen Winey, PhD, the Harold Pender Professor of Engineering and Applied Science at Penn Engineering. Learn more in Fierce Pharma here.